Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Scoops Up $20M in VC Cash for Product Development

NEW YORK, June 2 (GenomeWeb News) - Exiqon's has emerged from a third round of financing with $20 million in funding, the Danish company reported today.

The company plans to use the cash to support product development, sales and marketing, and loan repayment, according to a statement.

Exiqon is launching "a number" of miRURY microRNA analysis products "as well as other products," the company said. The firm recently signed a distribution agreement with Roche Diagnostics for its ProbeLibrary real-time PCR kits, Exiqon added.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.